- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04375657
Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial (TRIIM-X)
The TRIIM-X trial is an expanded pilot clinical study that will evaluate a personalized combination treatment regimen for thymus regeneration. The thymus is a part of the immune system that declines markedly with age, and regenerating it may prevent or reverse key aspects of immunosenescence (immune system aging) and potentially prevent or reverse key parts of the aging process more generally. The study will evaluate biomarkers for epigenetic aging and immunosenescence, as well as evaluate established clinical measures and risk factors for prevention of physical frailty, cancer, cardiovascular disease, diabetes, dementia, and also infectious diseases, including flu and COVID-19.
The study uses multiple agents in combination with personalized doses of recombinant human growth hormone (somatropin), metformin, and DHEA, in a similar manner to how the combination treatment was applied in the earlier TRIIM trial at Stanford, which demonstrated strong statistical significance for the primary efficacy endpoints that will be evaluated in TRIIM-X. Somatropin is approved by the FDA for adult growth hormone deficiency and its use in the study is guided by prior safety data established for that use and also based on safety data available on its prior use in the TRIIM trial and in clinical practice in healthy elderly individuals. There will also be control groups that enable testing of biomarker variability and the contribution of individual medications within the combination treatment.
The objective of the study is to obtain information needed for designing an effective personalized and adaptive treatment regimen for a larger and more diverse study population, and to obtain additional proof of principle for the new use of the medications and biomarkers for preventive medicine. The duration of treatment in the TRIIM-X trial will be 12 months.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Torrance, California, United States, 90502
- Recruiting
- Intervene Immune
-
Contact:
- Robert Brooke
- Phone Number: 833-346-6863
- Email: info@interveneimmune.com
-
Principal Investigator:
- Gregory M Fahy, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female volunteers
- Aged 40 to 80 years, inclusive
- All ethnicities
- Able to participate in 12-month study
- Able to provide informed consent
Exclusion Criteria:
- Malignancies or high risk of malignancy, as suggested by familial risk or personal medical history
- Premenopausal women
- Postmenopausal women on HRT
- IGF-1 levels < 90 ng/ml or >300 ng/ml
- Diagnosed or suspected growth hormone resistance
- Known growth hormone deficiency based on stimulation testing
- Pre-existing carpal tunnel syndrome
- Significant arthritis/arthralgia/joint swelling
- Bradycardia (<55 bpm), significant hypertension (systolic >160 mmHg, or diastolic >90 mmHg) despite treatment, serious angina, or other serious cardiovascular disease or cardiovascular disease risk factors
- Excessive skin growths (e.g., flat warts) without cryosurgical options
- BMI of 35 or greater
- PSA level above the age-adjusted normal range for reasons other than confirmed prostatitis
- Testosterone levels above the upper limit of normal
- Levels of C-reactive protein (CRP) above the upper limit of normal
- Type 1 or pre-existing Type 2 diabetes
- Uncorrected hypothyroidism
- HIV infection
- Allergy or other sensitivity to study medications
- Other unstable medical conditions
- Use of GH within the last 5 years
- Participation in a clinical research trial within 30 days prior to enrollment
- Use of chronic glucocorticoid therapy
- Unwilling to discontinue androgen supplementation if testosterone levels are above the upper limit of normal
- Ongoing treatment with carbonic anhydrase inhibitors
- Ketogenic diet, calorie-restricted diet, or prolonged fasting, without willingness to discontinue these diets or adhere to an alternative diet during the study
- Alcoholism or drug addiction
- Smoking or unwillingness to quit smoking
- Cognitive impairment, illiteracy, inability or unwillingness to give voluntary informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TRIIM Treatment
|
Personalized combination of somatropin, metformin, and DHEA
|
Active Comparator: Active Control
|
Metformin and DHEA
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Epigenetic Age
Time Frame: 12 months
|
DNA methylation based epigenetic age (GrimAge)
|
12 months
|
Thymus Regeneration
Time Frame: 12 months
|
Thymic density based on MRI or CT
|
12 months
|
Safety and Tolerability
Time Frame: 12 months
|
Incidence of treatment-related adverse effects
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunosenescence
Time Frame: 12 months
|
Assessment of naive T cells and immune cell function
|
12 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- TRIIM-X
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immunosenescence
-
Wageningen UniversityWageningen University and Research; Gelderse Vallei HospitalRecruiting
-
Centre Hospitalier Universitaire DijonWithdrawn
-
ClasadoUniversity of ReadingCompletedImmunosenescenceUnited Kingdom
-
Clinical Research Center Kiel GmbHUniversity of Bologna; Institut Pasteur; European Commission; Nofima; Teagasc; BioActor... and other collaboratorsCompleted
-
NIZO Food ResearchWageningen University; FrieslandCampinaCompletedInflammation | ImmunosenescenceNetherlands
-
University of Southern CaliforniaWithdrawnImmunosenescence
-
Central Arkansas Veterans Healthcare SystemUniversity of ArkansasCompletedSarcopenia | ImmunosenescenceUnited States
-
University of Colorado, DenverMerck Sharp & Dohme LLC; National Institute on Aging (NIA)CompletedImmunosenescence | ShinglesUnited States
-
Centre Hospitalier Universitaire, AmiensActive, not recruitingCovid19 | Seroconversion | Immunosenescence | Geriatric MedicineFrance
-
University Hospital, BordeauxRecruitingBehavioral Symptoms | Mental Disorders | Depression | Brain Diseases | Neurocognitive Disorders | Dementia | Anxiety | Alzheimer Disease | Aging | Mental Health | Immunosenescence | Cognition | Brain | Cognitive Aging | Mental ProcessesFrance
Clinical Trials on TRIIM Treatment
-
PfizerCompleted
-
PfizerCompleted
-
Chiesi Farmaceutici S.p.A.Completed
-
Gilead SciencesCompletedChronic Lymphocytic LeukemiaUnited States
-
PfizerCompleted
-
JW PharmaceuticalCompletedHealthyKorea, Republic of
-
AstraZenecaParexelCompleted
-
Assistance Publique - Hôpitaux de ParisRecruitingIntra-articular Fracture of the Mandibular CondyleFrance
-
PfizerCompletedHealthy VolunteersUnited States
-
New Mexico VA Healthcare SystemCompletedPost Traumatic Stress DisorderUnited States